Location: United States
Using artificial intelligence, TwoXAR is increasing the success rate of new drugs
Drug development is a slow process with a high failure rate, with each attempt costing billions of dollars. The costly, long process means new treatments can take years, even decades to hit the market. Rare diseases, which may be more challenging to find the financial support for, often go ignored.
A faster, more efficient approach to drug development is needed to ensure treatment is available for as many diseases as possible. TwoXAR is one of the startups leading the way in scalable drug discovery. In July 2020, they made Forbes list of America’s 50 most promising AI companies to watch. Using AI in drug discovery is a revolutionary field, with other companies like Benevolent AI and Deep Genomics making headway.
TwoXAR applies artificial intelligence to drug discovery to speed up the process of identifying potential treatments. Their research model can reduce the time to clinical trials by 3 years, and increases the chance of success by around 30 times. Currently, TwoXAR has 18 disease programs in its pipeline, including endometriosis, glaucoma, glioblastoma, liver cancer, and lupus.